Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
C4-MOSART: SBRT with Immuno-oncology Agents in Advanced Solid Tumors
NCT03431948Phase 1Completed
- Sponsor
- University of Chicago
- Start
- Mar 2018
- Primary completion
- Feb 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of cabiralizumab and urelumab in solid tumor (2 arms), sponsored by University of Chicago. Primary endpoint: Recommended dose of SBRT given in combination with immunotherapy at 3 months. Started Mar 2018; status: completed.
02
Drugs
cabiralizumaburelumab
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT03431948.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03431948.